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Abstract
Background: Metabolism remodeling has been recognized as an early event following cardiac pressure overload.
However, its temporal association with ventricular hypertrophy has not been confirmed. Moreover, whether
trimetazidine could favorably affect this process also needs to be determined. The aim of the study was to explore
the temporal changes of myocardial metabolism remodeling following pressure-overload induced ventricular
hypertrophy and the potential favorable effect of trimetazidine on myocardial metabolism remodeling.
Methods: A rat model of abdominal aortic constriction (AAC)-induced cardiac pressure overload was induced.
These rats were grouped as the AAC (no treatment) or TMZ group according to whether oral trimetazidine (TMZ,
40 mg/kg/d, for 5 days) was administered. Changes in cardiac structures were sequentially evaluated via
echocardiography. The myocardial ADP/ATP ratio was determined to reflect the metabolic status, and changes in
serum neuropeptide Y systems were evaluated.
Results: Myocardial metabolic disorder was acutely induced as evidenced by an increased ADP/ATP ratio within
7 days of AAC before the morphological changes in the myocardium, accompanied by up-regulation of serum
oxidative stress markers and expression of fetal genes related to hypertrophy. Moreover, the serum NPY and
myocardial NPY-1R, 2R, and 5R levels were increased within the acute phase of AAC-induced cardiac pressure
overload. Pretreatment with TMZ could partly attenuate myocardial energy metabolic homeostasis, decrease serum
levels of oxidative stress markers, attenuate the induction of hypertrophy-related myocardial fetal genes, inhibit the
up-regulation of serum NPY levels, and further increase the myocardial expression of NPY receptors.
Conclusions: Cardiac metabolic remodeling is an early change in the myocardium before the presence of typical
morphological ventricular remodeling following cardiac pressure overload, and pretreatment with TMZ may at least
partly reverse the acute metabolic disturbance, perhaps via regulation of the NPY system.
Keywords: Metabolic remodeling, Trimetazidine, Ventricular hypertrophy, Neuropeptide Y
* Correspondence: 1228327958@qq.com
7Department of Cardiology, Zhujiang Hospital of Southern Medical
University, Guangzhou 510280, China
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chen et al. BMC Cardiovascular Disorders  (2016) 16:225 
DOI 10.1186/s12872-016-0399-8
Background
Despite significance advances in therapeutic strategies
against congestive heart failure (CHF) during the past
few decades, CHF remains one of the most serious dis-
eases, contributing to substantial mortality and morbid-
ity throughout the world [1, 2]. Ventricular hypertrophy
and cardiac remodeling have been well established as
important pathologic events that play fundamental roles
during the pathogenesis of CHF [3, 4]. Indeed, various
stimuli of cardiac injury lead to impairment of cardiac
function and subsequently activation of neurohormonal
factors, which in the long-term, causes apoptosis of car-
diomyocytes, fibrosis and eventually hypertrophy of the
myocardium, finally leading to a vicious cycle of cardiac
function deterioration [5]. This pathogenetic process has
been known as ventricular remodeling, and inhibitors of
neurohormonal factors that are involved in the activa-
tion of ventricular remodeling have been recognized as
important therapeutic medications against CHF [6].
More importantly, subsequent studies have highlighted
the role of myocardial metabolic dysfunction as a poten-
tial pivotal process before ventricular remodeling begins
during the pathogenesis of CHF [7]. Hypertrophied myo-
cardium has been shown to be characterized by the dis-
turbance of homeostasis of energy metabolism [8–11].
Moreover, an interesting genomic study found that early
and acute changes in the expression of genes related to
energy metabolism can be detected before evidence of
cardiac remodeling [12], which indicates that disturb-
ance of myocardial biogenesis may be an initial process
and important contributor to cardiac remodeling. How-
ever, to the best of our knowledge, the acute changes in
energy status during the early phase of cardiac pressure
overload, a conventional stimulus of cardiac remodeling,
have not been systematically studied.
Neuropeptide Y (NPY) has been recognized as a key
regulator of energy metabolism via its binding and
signaling with its receptors (NPY-R) [13]. Previous
studies in human patients and animal models of CHF
have suggested that NPY may participate in the patho-
genesis of myocardial hypertrophy and subsequent CHF
[14–16]. However, whether the NPY system is involved
in the metabolism disturbance during the early phase of
cardiac pressure overload still needs to be determined.
Trimetazidine (TMZ) is used clinically as an anti-angina
medication, because it can improve energy metabolism
during the process of myocardial ischemia [17, 18].
Upon application of TMZ, the utilization of free fatty
acids for energy production is decreased in myocardium
due to its inhibitory effect on mitochondrial 3-ketoacyl
CoA thiolase (3-KAT) in beta-oxidation, and subse-
quently, the consumption of non-lipid substrates, mainly
glucose, is increased [19]. Recent studies suggested that
TMZ may inhibit pressure overload-induced cardiac
fibrosis and myocardial remodeling [20]. Therefore, it is
reasonable to speculate that TMZ, as a medication
capable of optimizing myocardial metabolism, may at-
tenuate the disturbance of myocardial energy metabol-
ism during the acute phase of pressure overload-induced
myocardial remodeling.
Based on the evidence presented above, we hypothe-
sized that myocardial metabolic disturbance may be an
early event before the morphological changes of myocar-
dial hypertrophy, and changes in the NPY system may
be involved. Moreover, pretreatment with TMZ may
attenuate the metabolic disturbance of the myocardium
before the morphological changes of ventricular hyper-
trophy can be detected, and these metabolic benefits of
TMZ may involve the regulation of serum and myocar-
dial NPY system. Therefore, in this study, we applied a
rat model of short-term (within 7 days) abdominal
aortic constriction (ACC)-related cardiac pressure over-
load but without significant morphological changes of
myocardial hypertrophy, to systematically observe the
changes of myocardial energy metabolism, potential
benefits of TMZ pretreatment, and the roles of the
NPY system involved.
Methods
The current study was performed in accordance with
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996). The exper-
iments protocols were approved ahead of performance
by the Committee on Ethics of Animal Experiments of
Guangzhou Medical University.
Animal models of cardiac pressure overload
Thirty-eight male Wistar rats, weighing 60 ± 10 g, were
purchased from the Animal Experimental Center of the
Southern Medical University. Rats were given free access
to food and water as needed, housed in a stable space
with the room temperature at 22 °C, and maintained on
a 12-h light/dark cycle for 7 days before the ACC
procedure.
These rats were randomized to three groups: (1) the
sham group (n =12), in which the surgical procedure of
ACC was performed in the same way except for ligation
of the abdominal aorta; (2) the AAC group (n = 13), in
which AAC was performed by ligation of the abdominal
aorta 5 mm above the branching of the left renal artery
to induce pressure overload of the heart, as described
previously [21, 22]; and (3) the TMZ group (n = 13), in
which the oral administration of TMZ (40 mg/kg/d, for
5 days) was performed before the surgical procedure for
AAC-induced cardiac pressure overload. Briefly, all sur-
gical procedures were performed after the rats were well
anesthetized with intraperitoneal sodium pentobarbital
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(45 ml/kg). The abdominal aorta, proximal to the left
renal artery was exposed and separated from the vena
cava. A 2-0 silk suture was tied beside the aorta between
the branches of the celiac and the anterior mesenteric
arteries, using a blunt 24 G probe with the external
diameter of 0.55 mm. After the above procedure, 1 ml
saline was administered in the peritoneal cavity of each
rat to replenish of the loss of the fluid during the pro-
cedure. Then, the abdominal wall was closed and the
skin was sutured. The rats in the sham group received
the same procedure expect that the silk suture around
the aorta was pulled through and not tied. Ampicillin
(50 mg/kg, i.m.) was injected once daily for 3 days
after surgery to prevent infection, and all rats were
placed on a warm pad for recovery after the surgery.
Overall, one rat from the AAC group and one rat
from the TMZ group died from acute heart failure
after the surgical procedure. Twelve rats in each
group survived the surgical procedures, and these rats
within each group were further divided in to two
groups (6 rats in each for the different observation
periods of 2 and 7 days).
Echocardiographic examination
The cardiac systolic function and dimensions of the
heart chambers were measured 2 and 7 days after sur-
gery, according to the different observation groups, by
two-dimensional echocardiography (Philips IE 33,) by an
experienced investigator who was blinded to the treat-
ment groups. Measurements were recorded as the mean
of at least three consecutive cardiac cycles. The parame-
ters recorded included interventricular septal thickness
at end diastole (IVSd), left ventricular posterior wall thick-
ness at end diastole (LVPWd), left ventricular end-
diastolic dimension (LVEDD), left ventricular end-systolic
dimension (LVESD), left ventricular factional shortening
(LVFS), and left ventricular ejection fraction (LVEF).
Blood sampling and measurements of serum levels of
NPY, MDA, and SOD activity
After echocardiologic examination, blood samples of rats
from each group were obtained via intubation of the
carotid artery. Immediately, blood samples were centri-
fuged at 12,000 g for 10 min at 4 °C, and then the super-
natant was collected for measurement at −20 °C. Serum
levels of NPY were measured using a commercially avail-
able enzyme immunoassay (EIA) kit (Bachem Laborator-
ies, S-1145), and the experimental procedures were
performed according to the manufacturers’ procedures.
Similarly, the serum level of malonaldehyde (MDA) and
serum superoxide dismutase (SOD) activity were evalu-
ated using a suite of commercial kits, in accordance with
the manufacturer’s instructions (Beyotime Institute of
Biotechnology, Nanjing, China).
Determining the ratio of heart to body weight
After blood sampling, the rats were sacrificed, and
hearts from rats in each group were excised. The heart
weight (HW) was obtained as well as the weight of the
left ventricle (LVW). Subsequently, the ratio of HW to
body weight (BW) (HW/BW) was calculated. After
measurement, the left ventricle sample was excised,
rinsed with ice-cold saline, and dried with blotting
paper. Next, the myocardial sample was placed in a
microtube, flash frozen in liquid nitrogen, and finally
stored at −80 °C for use in subsequent molecular
biological experiments.
Measurement of cell surface area
Some myocardial tissue samples were fixed in 4% for-
maldehyde and embedded in paraffin. These tissues were
then sectioned at 5 μm and stained with hematoxylin
and eosin (HE). The cell surface area (CAS) of cardio-
myocytes was then measured and analyzed with IPP6.0
Software (Leica, Germany). At least 100 cells were
selected for analysis from each section of the myocardial
tissue.
ADP/ATP ratio assay
To assess the energy status of the myocardial tissue, an
ADP/ATP ratio assay was performed using the ApoSEN-
SOR™ ADP/ATP Ratio Assay Kit (MBL, Nagoya, Japan)
according to the manufacturer’s instructions.
Quantitative real-time PCR
Total RNA from myocardial tissue samples of rats in
each group were extracted using Trizol reagent (Invitro-
gen Life Technologies, Thermo Fisher Scientific) and
reverse transcribed into cDNA (Advantage RT-for-PCR
kit; Clontech, Palo Alto, CA, USA) for subsequent
analysis of the mRNA levels of myocardial hypertrophy-
related genes including atrial natriuretic factor (ANF)
and β myosin heavy chain (MHC-β), as well as NPY-1R,
2R, and 5R. Briefly, 1 μg of total RNA was reverse tran-
scribed using 2 μg of random primers and Moloney
murine leukemia virus reverse transcriptase according
to the manufacturer’s protocol (Advantage RT-for-PCR
kit). We used a One-Step system (Applied Biosystems,
Thermo Fisher Scientific) to perform the real-time PCR
analysis. The sequences of the primers for the genes an-
alyzed are listed in Table 1. We applied the relative
quantitation method to measure the expression levels
of the genes of interest and analyzed the results of two
independent experiments with triplicate sampling. For
each experimental sample, a gene was considered as
not expressed if amplification was not detected by
threshold cycle Ct = 40. The results were expressed in
arbitrary units of ΔCt, which represented targeted
mRNA transcripts.
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Western blot analyses
Total proteins in myocardial tissue samples were ground
and homogenized with a protein lysis solution (KeyGen
BioTech, China). Briefly, myocardium form the LV was
frozen in liquid nitrogen and then homogenized in
phosphate-buffered saline (PBS) with a protease inhibitor
cocktail (Roche, South San Francisco, CA, USA) using a
tissue grinder. Homogenates were centrifuged at
14,000 rpm for 15 min at 4 °C. Nuclear and cytoplasmic
proteins were separated according to the protocol de-
scribed in the Nuclear and Cytoplasmic Extraction Kit
(Thermo Scientific, USA). Supernatants were collected
and assayed for total protein using the BCA method
(KeyGen BioTech, China). Equal amounts of protein
(125 μg) were resolved on 10% Tris-glycine sodium dode-
cyl sulphate (SDS) polyacrylamide gels. Protein bands
were blotted onto nitrocellulose membranes. After block-
ing in 5% dried milk in Tris-buffered saline containing
Tween-20 for 1 h at room temperature, membranes were
incubated for 24 h at 4 °C with one of the following anti-
bodies: anti-NPY-1R polyclonal antibody (Abnova, Taiwan,
China), anti-NPY-2R (D42) pAb (Bioworld, USA), anti-
NPY-5R (M264) pAb (Bioworld), and anti GAPDH
(14C10) Rabbit mAb (Cell Signaling Technology, USA) to
detect the proteins levels. Membranes were incubated for
1 h at room temperature with horseradish peroxidase-
conjugated donkey anti-rabbit immunoglobulin (1:10,000;
Santa Cruz Biotechnology). Peroxidase labeling was de-
tected using the enhanced chemiluminescence Western
blotting detection system (Amersham Pharmacia Biotech,
Piscataway, NJ, USA) and analyzed by densitometry. The
optical density values were normalized to that of GAPDH.
Statistical analyses
Statistical analyses were performed using SPSS 11.0
(SPSS Inc., Chicago, IL, USA). The results are reported
as mean ± standard deviation (SD). Differences were
analyzed for significance by one-way or two-way analysis
of variance (ANOVA), and p < 0.05 was considered to be
statistically significant.
Results
Effects of TMZ on left ventricular hypertrophy and cardiac
function in AAC rats
To observe the acute impact of pressure overload on
cardiac hypertrophy and cardiac function, we measured
the dimensions of the left ventricle and cardiac systolic
function via echocardiography. The results of the echo-
cardiographic examination showed that the parameters
of left ventricular dimensions, such as IVSd, LVPWd,
LVEDD, and LVESD, as well as the indices of cardiac
systolic function, including LVFS and LVEF, were not
significantly different between the rats from the sham
and AAC groups at 2 or 7 days after AAC (Table 2).
Moreover, the results of the gross and cellular pathologic
studies revealed that the ratios of HW/BW and LVW/
BW and the CSA of the cardiomyocytes of rats in the
sham and AAC groups also were not significantly differ-
ent at 2 or 7 days after AAC (Fig. 1a-c). These results
indicate that acute pressure overload did not cause sig-
nificant changes in cardiac structure or cellular morph-
ology, suggesting that myocardial hypertrophy or cardiac
systolic dysfunction was not induced within 7 days of
AAC. Moreover, pretreatment with TMZ was not associ-
ated with significant changes in the echocardiologically
detected cardiac structure or systolic function or the
ratios of HW/BW and LVW/BW and the CSA of the
cardiomyocytes (Table 1, Fig. 1a-c). These results further
indicate that pretreatment with TMZ did not affect the
cardiac structure or cellular morphology during the
acute phase of AAC (up to 7 days).
Effects of TMZ on expression of genes related to
myocardial hypertrophy in AAC rats
Up-regulated expression of fetal genes, such as ANF and
MHC-β, has been recognized as an important feature of
the pathogenesis of myocardial hypertrophy [23]. There-
fore, we evaluated the acute effects of AAC on the
expression of these hypertrophy-related genes, and more
importantly, the influence of pretreatment with TMZ on
expression of these genes. The results of real-time PCR
indicated that the mRNA levels of ANF and MHC-β
were significantly increased in the myocardium of rats
from the AAC group in comparison with those from the
sham group both at 2 and 7 days after AAC (p < 0.05,
Fig. 2a-b). Moreover, we also found that pretreatment
with TMZ inhibited the upregulation of these genes
induced by acute AAC as indicated by significantly
reduced levels of expression of these genes in the myo-
cardium of rats in the TMZ group as compared with
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those of the AAC group (p < 0.05, Fig. 2). These
results suggest that pretreatment with TMZ may
inhibit the early upregulation of fetal genes related to
myocardial hypertrophy following the acute phase of
cardiac pressure overload.
Effects of TMZ on ratio of ADP/ATP and serum activities
of MDA and SOD
Previous studies confirmed that the ratio of ADP/ATP is
an index of energy metabolism in the myocardium, and
disturbance of cardiac energy biogenesis is often associ-
ated with an increased ADP/ATP [24]. In this study, we
found that acute cardiac pressure overload increased the
myocardial ADP/ATP at 2 and 7 days after AAC (p < 0.05,
Fig. 3). Notably, these changes in metabolic dysfunction
seemed to appear before the significant and typical
changes in cardiac structure and morphology seen during
the late process of AAC. Interestingly, pretreatment with
TMZ significantly reduced the myocardial ADP/ATP
following AAC (p < 0.05, Fig. 3), suggesting that TMZ may
favorably affect the energy metabolism of the myocardium
even in the acute phase of cardiac pressure overload.
Similarly, the significantly increased serum levels of MDA
and SOD, which have been considered markers of oxida-
tive stress-related injury detected during the process of
energy metabolic dysfunction [25], also were significantly
lowered at 2 days after AAC in the rats pretreated with
TMZ (p < 0.05, Fig. 4a-b). These results indicate that
cardiac pressure overload may induce energy metabolic
disorder and oxidative stress-related injury before the
typical changes of myocardial hypertrophy could be
observed, and pretreatment with TMZ may attenuate
such disorder of energy biogenesis during the acute
phase of AAC.
Effects of TMZ on the serum NPY levels and myocardial
expression of NPY receptors
The results of early studies indicated that NPY is an
important neurohormonal factor that may function as a
key regulator of energy metabolism [13]. In view of the
fact that pretreatment with TMZ may attenuate of the
disturbance of energy metabolism during the acute
phase of AAC, we further evaluated the role of NPY and
its receptors during the pathogenesis of cardiac pressure
overload, as well as the influence of TMZ pretreatment
on them. We found that plasma NPY levels were signifi-
cantly increased at 2 and 7 days after AAC as compared
with those in the sham group (p < 0.05, Fig. 5), whereas
pretreatment with TMZ significantly inhibited the up-
regulation of serum NPY during the acute phase of AAC
(p < 0.05, Fig. 5), suggesting that the favorable effect of
TMZ on myocardial energy biogenesis may be related to
its inhibitory effect on serum NPY. Moreover, the
mRNA levels of myocardial NPY-1R, 2R, and 5R were
increased during the acute phase of cardiac pressure
overload (p < 0.05, Fig. 6a-c), and the mRNA levels of
NPY-1R and 2R were further up-regulated following
TMZ pretreatment (p < 0.05, Fig. 6a-c). However, the
mRNA level of NPY-5R was not significantly changed
upon TMZ pretreatment as compared with that from
the AAC group (p > 0.05, Fig. 6c). The results of western
blot analyses seemed to parallel those of the mRNA
expression analyses. Protein levels of NPY-2R and 5R
were increased at 2 days after AAC, and the protein
levels of NPY-1R and 2R were further up-regulated
following pretreatment with TMZ at 2 days after AAC
(Fig. 7a). By 7 days after AAC, protein levels of myocar-
dial NPY-2R and 5R were upregulated, whereas protein
levels of all three NPY receptors were further up-
regulated after TMZ pretreatment (Fig. 7b). These
results suggest that acute cardiac pressure overload may
have contributed to early energy dysfunction by inducing
the neurohormonal factor NPY and up-regulating NPY-
2R and 5R, whereas pretreatment with TMZ attenuated
the induction of NPY but further stimulated the protein
levels of myocardial NPY receptors.
Discussion
Our study in a rat model of AAC-induced cardiac pres-
sure overload revealed that myocardial energy metabolic
Table 2 Echocardiologic evaluation of cardiac function at 2 and 7 days after AAC
2 days after AAC 7 days after AAC
Sham AAC AAC + TMZ P values Sham AAC AAC + TMZ P values
IVSd (mm) 0.95 ± 0.12 1.00 ± 0.05 1.01 ± 0.06 >0.05 1.10 ± 0.03 1.21 ± 0.07 1.24 ± 0.11 >0.05
LVPWd (mm) 1.30 ± 0.40 1.63 ± 0.07 1.64 ± 0.04 >0.05 1.45 ± 0.19 1.67 ± 0.12 1.65 ± 0.23 >0.05
LVEDD (mm) 4.30 ± 0.27 4.53 ± 0.39 4.52 ± 0.26 >0.05 4.50 ± 0.28 4.90 ± 0.09 5.03 ± 0.12 >0.05
LVESD (mm) 2.46 ± 0.11 2.52 ± 0.09 2.51 ± 0.07 >0.05 2.49 ± 0.07 2.62 ± 0.24 2.64 ± 0.18 >0.05
LVFS (%) 37.97 ± 9.05 44.66 ± 10.04 45.27 ± 8.13 >0.05 38.63 ± 8.15 44.56 ± 1.89 43.68 ± 2.78 >0.05
LVEF (%) 73.47 ± 10.51 85.40 ± 1.91 84.23 ± 2.32 >0.05 79.5 ± 3.41 86.09 ± 3.19 84.48 ± 2.67 >0.05
Data are presented as mean ± SD, n = 6 per group
AAC aortic artery constriction, IVSd interventricular septal thickness at end diastole, LVPWd left ventricular posterior wall thickness at end diastole, LVEDD left
ventricular end-diastolic dimension, LVESD left ventricular end-systolic dimension, LVFS left ventricular factional shortening, LVEF left ventricular ejection fraction,
TMZ trimetazidine
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disorder was acutely induced within 1 week after AAC,
which was before the typical morphologic changes of
ventricular hypertrophy occurred. Moreover, disturbance
of myocardial energy metabolism was accompanied by
up-regulation of serum levels of oxidative stress markers
and expression of myocardial fetal genes related to
ventricular hypertrophy. Interestingly, the serum level of
NPY and myocardial mRNA and protein levels of NPY-
1R, 2R, and 5R also were increased within the acute phase
of AAC-induced cardiac pressure overload. More import-
antly, pretreatment with TMZ could partly attenuate
myocardial energy metabolic disturbance, decrease serum
levels of oxidative stress markers, attenuate the induction
of hypertrophy-related myocardial fetal genes, inhibit the
up-regulation of serum NPY levels, and further increase
the myocardial expression of NPY receptors. These results
confirmed previous findings that energy metabolic disor-
ders may occur prior to typical morphological changes of
ventricular hypertrophy following cardiac pressure over-
load, suggesting a potential pathophysiologic process of
metabolic remodeling before myocardial remodeling be-
gins. Moreover, our results for the first time suggest that
pretreatment with TMZ, a medication known for its bene-
fits in cardiac energy metabolism, may attenuate the early
energy metabolic disturbance of the myocardium during
the acute phase of AAC-induced cardiac pressure over-
load. With respect to the mechanisms underlying the
energy remodeling following AAC, we found that changes
in serum NPY and myocardial NPY receptor levels may be
involved, and TMZ may exert its beneficial effect via
Fig. 2 Comparisons of myocardial expression of fetal genes related
to myocardial hypertrophy induced by AAC: results of real-time PCR
analyses. a, Effects of AAC and TMZ pretreatment on mRNA levels of
MHC-β in myocardium of rats from each group; b, effects of AAC
and TMZ pretreatment on mRNA levels of ANF in myocardium of
rats from each group. AAC abdominal aortic constriction, TMZ
trimetazidine, ANF atrial natriuretic factor, MHC-β β myosin heavy
chain; n = 4~6 per group, and samples were analyzed in triplicate.
*, p < 0.05 compared with sham group at the same time point; #,
p < 0.05 compared with AAC group at the same time point
Fig. 1 Comparisons of the heart weight, left ventricular weight, and
cell surface area of cardiomyocytes for rats from each group. a,
Effects of AAC and TMZ pretreatment on HW/BW in rats from each
group; b, effects of AAC and TMZ pretreatment on LVW/BW in rats
from each group; c, effects of AAC and TMZ pretreatment on CSA of
cardiomyocytes for rats from each group. AAC abdominal aortic
constriction. TMZ trimetazidine, HW heart weight, BW body weight,
LVW left ventricular weight, CSA cell surface area; n = 6 per group; 10
high magnification views with at least 100 cardiomyocytes in each
view were analyzed to determine the CSA
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regulation of the NPY system. These results highlight the
importance of cardiac metabolic remodeling as an early
change in the myocardium before the presence of typical
morphological ventricular remodeling and suggest that
early treatment with TMZ may attenuate the disturbance.
Early studies revealed that disturbance of myocardial
energy metabolism, which typically presents as an in-
creased ratio of cellular ADP/ATP, plays important roles
in the pathogenesis of CHF [7, 9]. Although this has
been proposed in early observations, whether metabol-
ism remodeling occurs before or after the structural
changes of myocardial hypertrophy has not been deter-
mined until recent years. A genomic study of pressure
overload-induced cardiac hypertrophy in mice found
early changes in the expression of metabolic genes
before the hypertrophic phase of the myocardium [12].
A later study with the same animal model using the
quantitative positron emission tomography (PET) im-
aging also indicated that metabolic maladaptation pre-
cedes the onset of severe contractile dysfunction [26]. A
recent study in patients with hypertension provided
more direct evidence supporting that metabolic remod-
eling is an early event that occurs before the onset of
cardiac hypertrophy. With PET imaging, the investiga-
tors found that glucose metabolic remodeling is detect-
able in hypertensive patients before the development of
ventricular hypertrophy [26]. Our study, using an acute
model of AAC-induced cardiac pressure overload gener-
ated before the presence of typical morphologic changes
of ventricular hypertrophy (usually occurring at least
2 weeks after AAC), found that the ADP/ATP was sig-
nificantly increased, suggesting an occurrence of energy
metabolic disturbance before myocardial hypertrophy.
Further studies are needed to determine whether strat-
egies targeting early metabolic remodeling could prevent
subsequent myocardial structural remodeling.
Fig. 5 Comparison of serum concentrations of NPY in rats from
each group. AAC abdominal aortic constriction, TMZ trimetazidine,
NPY neuropeptide Y; n = 4~6 per group and samples were analyzed
in triplicate. *, p < 0.05 compared with sham group at the same time
point; #, p < 0.05 compared with AAC group at the same time point
Fig. 4 Comparisons of serum activities of oxidative stress markers. a,
Effects of AAC and TMZ pretreatment on MDA concentrations in rats
from each group; b, effects of AAC and TMZ pretreatment on SOD
activities in rats from each group. AAC abdominal aortic constriction,
TMZ trimetazidine, MDA malonaldehyde, SOD superoxide dismutase;
n = 4~6 per group and samples were analyzed in triplicate. *, p < 0.05
compared with sham group at the same time point; #, p < 0.05
compared with AAC group at the same time point
Fig. 3 Comparison of ADP/ATP ratios in myocardium. AAC
abdominal aortic constriction, TMZ trimetazidine; n = 4~6 per group
and samples were analyzed in triplicate. *, p < 0.05 compared with
sham group at the same time point; #, p < 0.05 compared with AAC
group at the same time point
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In view of the fact that TMZ may function to optimize
myocardial energy metabolism, we further evaluated
whether pretreatment with TMZ could attenuate the
metabolism dysfunction during the acute phase of AAC.
We found that TMZ not only significantly reversed the
changes in myocardial ADP/ATP, but also reduced the
serum levels of oxidative stress markers and the myocardial
expression of up-regulated fetal genes related to hyper-
trophy. These results suggest that TMZ may effectively
attenuate the metabolic disorder and therefore subse-
quently inhibit myocardial hypertrophy. Our results are
supported by the findings of Liu et al., which showed that
TMZ can inhibit myocardial fibrosis, a characterized fea-
ture of ventricular remodeling [6], as well as the fact that
application of TMZ in patients with CHF is associated with
a significantly reduced LVEDD (−6.05 mm) and improved
prognosis on the basis of optimized medical treatments for
CHF [27].
Previous studies have suggested that NPY is a potential
regulator of energy homeostasis, but whether it is an
important regulator of metabolic remodeling during the
acute phase of AAC-induced cardiac pressure overload
has not been determined. In this study, we found that
serum NPY was immediately induced by 2 days after
AAC, as was myocardial expression of the NPY recep-
tors, suggesting that the NPY system may be involved in
the process of early energy disturbance of the myocar-
dium. Previous studies in patients with end stage renal
disease indicated that elevated NPY is independently
associated with LV concentric hypertrophy and systolic
dysfunction [14]. Moreover, an NPY-Y2R polymorphism
may interact and influence such an association [28], sug-
gesting a potential role for the NPY system in the patho-
genesis of ventricular hypertrophy. Similarly, a study in a
rat model of CHF induced by aortocaval fistula indicated
that increased NPY and its interactions with NPY recep-
tors are involved in cardiac remodeling [16]. A recent in
vitro study found that NPY may damage the integrity of
mitochondrial structure and therefore disrupts energy
metabolism in cultured cardiomyocytes [29]. The results
of the above studies, in combination with ours, suggest
that NPY and its receptors in the myocardium may
mediate the early metabolic dysfunction in the acute
phase of AAC-induced cardiac pressure overload, and
TMZ may benefit the myocardium during this process
by modulating the NPY system. As for the potential
mechanisms underlying the potential regulatory effect of
TMZ on the NPY system seen in our study, some previ-
ously published studies may provide some evidence. A
previous study indicated that TMZ effectively inhibits
myocardial fibrosis via attenuation of reactive oxygen
species (ROS)-related myocardial injury [20]. Interest-
ingly, ROS have been suggested to be an upstream
stimulator of the systematic NPY system in the neural
tissue [30, 31]. Therefore, TMZ may regulate the NPY
system via its inhibitory effect of ROS. Specifically,
the exact molecular mechanisms underlying the role
of the NPY system in the pathogenesis of pressure
overload-induced acute metabolic remodeling and the
potential functions of different NPY receptors warrant
further investigation.
Our study has limitations that should be considered
when interpreting the results. First, because our study
Fig. 6 Comparisons of mRNA levels of NPY-1R (a), NPY-2R (b), and
NPY-5R (c) in the myocardium of rats from each group: results of
real-time PCR analyses. TMZ trimetazidine, NPY neuropeptide Y; n = 4~6
per group and samples were analyzed in triplicate. *, p < 0.05
compared with sham group at the same time point; #, p < 0.05
compared with AAC group at the same time point
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was designed to explore the temporal changes in myocar-
dial metabolism remodeling following pressure-overload
induced ventricular hypertrophy and the potential favor-
able effect of TMZ on myocardial metabolism remodeling,
we are most interested in the changes in metabolism-
related parameters before significant morphological myo-
cardial hypertrophy. Therefore, we chose 7 days of AAC
as the main exposure factor. The changes in myocardial
metabolism remodeling and potential effects of TMZ after
7 days of AAC should be evaluated in further studies.
Moreover, myocardial ADP/ATP, although an important
index of myocardial energy status, was not sufficient to
reflect the metabolic status of the myocardium following
acute pressure overload. Changes in many other parame-
ters related to myocardial energy metabolism, such as
myocardial expression of fatty acid or glucose oxidation
genes and insulin signaling genes, should be investigated.
Finally, the serum level of NPY may not be necessarily
correlated with their levels in myocardium. This is import-
ant, because we did observe that although NPY expression
in the serum decreases with TMZ treatment, the expres-
sion of NPY-Rs in the myocardium actually increases,
which in our point of view, may be a feedback response of
myocardium to the decreased serum NPY. The results of
our study could only provide associations between
changes of NPY system and TMZ treatment, and the
physiological influence and subsequent signaling pathways
of changes of NPY system deserve further investigation.
Conclusions
In conclusion, our study found that cardiac metabolic
remodeling is an early change occurring in the myocardium
before the observance of typical morphological ventricular
remodeling following cardiac pressure overload, and pre-
treatment with TMZ may at least partly reverse the acute
metabolic disturbance, perhaps via regulation of the NPY
system. Further studies are needed to clarify the exact
molecular mechanisms and potentially distinct role of
NPY receptors during this pathogenesis process.
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